Stephen Freedland, MD
Urology · West Hollywood, CANPI 1760572937
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,339,992 of the $1,937,274 with a category attached, or 69.2%. 27 manufacturers reported payments, led by Pfizer at 38.1% of the total. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 688 payments — averaging $2815.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$738K
- Sanofi$354K
- Astellas Pharma Europe Ltd$241K
- Astellas Pharma US Inc$124K
- Astellas Pharma Global Development$121K
- Janssen Global Services, LLC$89K
- plus $269K from 21 others
Across 271 payments — averaging $55,184 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$13.6M
- Merck$893K
- Blue Earth Diagnostics$283K
- Pfizer$137K
- Astellas Pharma Global Development$15K
- Ortho-clinical Diagnostics, Inc.$11K
- plus $5K from 3 others
What the payments were for
- Consulting fees$1,339,99269%
- Speaking & faculty fees$373,67319%
- Travel & lodging$211,22411%
- Food & beverage$12,3851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 158 | $738,036 |
| Sanofi | 165 | $354,389 |
| Astellas Pharma Europe Ltd | 57 | $241,299 |
| Astellas Pharma US Inc | 69 | $124,458 |
| Astellas Pharma Global Development | 39 | $121,295 |
| Janssen Global Services, LLC | 9 | $89,258 |
| AstraZeneca | 64 | $82,956 |
| Merck | 48 | $76,687 |
| Janssen Scientific Affairs, LLC | 15 | $30,547 |
| Bayer | 20 | $28,561 |
| Novartis | 6 | $14,904 |
| Boston Scientific | 13 | $8,000 |
| Janssen Research & Development, LLC | 3 | $7,423 |
| Eli Lilly | 2 | $6,400 |
| Ferring Pharmaceuticals Inc. | 2 | $5,044 |
| Ortho-clinical Diagnostics, Inc. | 1 | $2,275 |
| Tolmar, Inc. | 1 | $2,250 |
| Astrazeneca UK Limited | 1 | $1,745 |
| Astellas Pharma Inc | 7 | $1,502 |
| Johnson & Johnson | 1 | $73 |
| Telix Pharmaceuticals | 1 | $40 |
| Blue Earth Diagnostics | 1 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $31 |
| Myovant Sciences Inc. | 1 | $21 |
| AbbVie | 1 | $17 |
| BD | 1 | $16 |
| Ambu Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$966,591
- JEVTANA$313,726
- TALZENNA$142,978
- Erleada$111,609
- LYNPARZA$72,590
- ORGOVYX$27,300
- Nubeqa$20,125
- GENERAL BPH$7,502
- PLUVICTO$7,088
- VITROS$6,825
- FIRMAGON$5,013
- Non-Covered$1,680
- NO PRODUCT DISCUSSED$287
- GreenLight XPS$161
How this compares
$1,937,274 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 67 | $72,367 |
| Tamsulosin Hcl | 150 | $2,345 |
| Finasteride | 71 | $979 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 26 | $617 |
| Oxybutynin Chloride ErOxybutynin Chloride | 31 | $558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $124,458 | $72,36767 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in West Hollywood
- Andrew HungWest Hollywood$84K
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.